The Lonza Board of Directors announced today the nomination of Stephen Fry as an Independent Member of the Board, pending election at the Lonza Group Annual General Meeting in May 2026. If elected, Fry will also join the People and Governance Committee and the Audit and Compliance Committee.
Fry brings over three decades of pharmaceutical industry experience, having spent his entire career at Eli Lilly and Company. He served as Executive Vice President and Chief Human Resources Officer for 12 years, where he led large-scale organizational transformation and shaped high-performance cultures. His global leadership perspective and expertise in organizational governance, succession planning, and people strategy development are expected to complement the existing board capabilities.
Jean-Marc Huet, Chairman of the Lonza Board, stated that Fry's appointment will help develop and embed a performance culture within the company, supporting its ambition to attract and retain world-leading talent. This nomination comes as Lonza, the world's largest contract development and manufacturing organization (CDMO), continues to focus on innovation and operational excellence to serve the healthcare industry.
Lonza reported sales of CHF 6.5 billion and CORE EBITDA of CHF 2.1 billion in Full-Year 2025, highlighting its significant role in bringing life-saving therapies to patients worldwide. The company operates across five continents with approximately 20,000 employees.
For more information about Lonza, visit www.lonza.com. The original press release is available on www.newmediawire.com.
